Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck - Hanna, G J; O'Neill, A; Shin, K Y (Clin Cancer Res, 2022)